You take Wockhardt, Ranbaxy, Strides Arcolab, all these companies, all these names have sort of a problem with the FDA. In an interview with ET Now, Praful Bohra, Sr Research Analyst, Pharma, Nirmal Bang, shares his outlook for some pharma stocks. Excerpts: ... Economic Times, 2 weeks ago
Enter Natco Pharma at around Rs 700: Praful Bohra - Money Control, 2 weeks ago
Don't see any fundamental movement in Ranbaxy, Wockhardt: Praful Bohra, Nirmal Bang - Economic Times, 2 weeks ago
1 images for "praful bohra"
Operations here and in other countries continue to fare well; earnings growth to pick up in FY15 as new US product launches gain momentum Ujjval Jauhari | Mumbai April 9, 2014 Last Updated at 21:42 IST Glenmark Pharmaceuticals has seen an increase ...Business Standard India, 1 week ago US approvals hold key to Glenmark's prospects Business Standard India, 1 week ago
Shares of Natco Pharma ended 5 percent higher after US patent office rejected Teva's patent reissue application on Copaxone. This, however, does not change the US Supreme Court hearing but makes a stronger case for Natco and Mylan. In its ruling, ...Moneycontrol.com, 1 week ago
W However, there is a likelihood of Natco Phrama going in for an at risk launch around May after all the necessary approvals are received, he said. Teva is the innovator of the multiple sclerosis drug Copaxone . SC ruling in favour of Teva may ...Moneycontrol.com, 2 weeks ago Natco’s launch of Copaxone in May 'at risk': Nirmal Bang Money Control, 2 weeks ago
03.40 p.m. Markets end at record high. Sensex closes at 22,214, up 119 points, Nifty ends at 6,642 after rising 40 points. State-run lenders emerged as the biggest gainers and pharma stocks were the top underperformers. SBI and PNB gained on broker ...NDTV Profit, 2 weeks ago Share market live: Nifty struggles near 6,650; SBI soars NDTV Profit, 3 weeks ago Share market live: Nifty edges above 6,650 to record high NDTV, 3 weeks ago
Pharma stocks are on track for a fourth straight losing session on Thursday. The BSE healthcare index, which comprises of well-known drugmakers, traded 0.7 per cent lower as of 12.50 p.m., underperforming the broader Sensex, which gained 0.5 per ...NDTV Profit, 3 weeks ago
The rising regulatory hurdles for Indian pharmaceutical companies in the US could prove a blessing for American generic medicine manufacturers. While leading Indian drug makers are inreasingly facing enforcement action as well as reputational ...Smart Investor, 3 weeks ago
on your WebpageAdd Widget >Get your members hooked!